
Erlotad 100 Tablet
Marketer
Adley Formulations
Salt Composition
Erlotinib (100mg)
Overview Erlotad 100 Tablet
Erlotad 100mg tablets treat non-small cell lung and pancreatic cancers. Administer this medication on an empty stomach, or at least one hour before or two hours after eating. Continue treatment as directed by your physician; its duration depends on individual needs and response. Strictly follow your doctor's instructions; incorrect usage or overdose can lead to severe adverse effects. Therapeutic benefits may take weeks or months to manifest; do not discontinue use without your doctor's consent. Common side effects include nausea, vomiting, tiredness, skin rashes, and weight loss. Severe diarrhea requires increased fluid intake or medical attention. Photosensitivity is possible; wear protective clothing and sunscreen outdoors. Report mouth sores, vision changes, or breathing problems immediately. Regular liver function monitoring may be necessary. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; effective contraception is crucial for both partners. Smoking cessation is recommended during treatment to optimize therapeutic efficacy. If using antacids or other medications, maintain a two-hour interval between administrations.
Uses of Erlotad 100 Tablet
Cancers of the pancreas and non-small cell lung
Major Benefits of Erlotad 100 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the entire tablet without chewing, crushing, or breaking it. Erlotad 100 Tablets should be administered on an empty stomach.
Common Side effects of Erlotad 100 Tablet:
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
How to use Erlotad 100 Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Erlotad 100 Tablet on an empty stomach.
How Erlotad 100 Tablet works:
Erlotad 100 tablets are an anti-neoplastic agent targeting lung cancer. Lung cancer cells utilize epidermal growth factor receptors (EGFR) to stimulate their proliferation. This medication functions by attaching to EGFR, thereby disrupting the EGFR-mediated signaling cascades responsible for cancer cell growth, ultimately curbing tumor expansion.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The interaction of alcohol with Erlotad 100 Tablet is not established. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Erlotad 100 Tablet during pregnancy poses a confirmed risk to the fetus. Its use is contraindicated except in potentially life-threatening circumstances where the physician deems the benefits outweigh the risks. Seek medical advice before taking this medication.
Breast feedingCONSULT YOUR DOCTOR
The use of Erlotad 100 Tablet while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Erlotad 100 Tablet on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Erlotad 100 Tablet presents no safety concerns for individuals with kidney impairment; dosage modification is unnecessary. However, its use is contraindicated in patients exhibiting severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should exercise caution when using Erlotad 100mg tablets; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Erlotad 100 Tablet :
Omit any missed Erlotad 100 Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Erlotad 100 Tablet
| Label | Value |
|---|---|
| Chemical Type | Quinazoline-based compound |
| Developing Habits | No. |
| Treatment Category | Cancer Treatments |
